Generic placeholder image

Current Alzheimer Research


ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Small Molecules and Alzheimer’s Disease: Misfolding, Metabolism and Imaging

Author(s): Shahrzad Abdollahi, Ian V.J. Murray, Tuula O. Jalonen, Chongzhao Ran, Janelle N. Fawver, Karen T. Duong, Nikhita Gadi, Rachel A. Gonnella, Stacey Charles, Viharkumar Patel, Pardeep S. Taunk, Hee Chang Sung, Melvin Baidya, Opeyemi O. Owa, Akwe N. Nyabera, Nicolas A. Tautiva and Xueli Zhang

Volume 12 , Issue 5 , 2015

Page: [445 - 461] Pages: 17

DOI: 10.2174/1567205012666150504145646

Price: $65


Small molecule interactions with amyloid proteins have had a huge impact in Alzheimer's disease (AD), especially in three specific areas: amyloid folding, metabolism and brain imaging. Amyloid plaque amelioration or prevention have, until recently, driven drug development, and only a few drugs have been advanced for use in AD. Amyloid proteins undergo misfolding and oligomerization via intermediates, eventually forming protease resistant amyloid fibrils. These fibrils accumulate to form the hallmark amyloid plaques and tangles of AD. Amyloid binding compounds can be grouped into three categories, those that: i) prevent or reverse misfolding, ii) halt misfolding or trap intermediates, and iii) accelerate the formation of stable and inert amyloid fibrils. Such compounds include hydralazine, glycosaminoglycans, curcumin, beta sheet breakers, catecholamines, and ATP. The versatility of amyloid binding compounds suggests that the amyloid structure may serve as a scaffold for the future development of sensors to detect such compounds. Metabolic dysfunction is one of the earliest pathological features of AD. In fact, AD is often referred to as type 3 diabetes due to the presence of insulin resistance in the brain. A recent study indicates that altering metabolism improves cognitive function. While metabolic reprogramming is one therapeutic avenue for AD, it is more widely used in some cancer therapies. FDA approved drugs such as metformin, dichloroacetic acid (DCA), and methylene blue can alter metabolism. These drugs can therefore be potentially applied in alleviating metabolic dysfunction in AD. Brain imaging has made enormous strides over the past decade, offering a new window to the mind. Recently, there has been remarkable development of compounds that have the ability to image both types of pathological amyloids: tau and amyloid beta. We have focused on the low cost, simple to use, near infrared fluorescence (NIRF) imaging probes for amyloid beta (Aβ), with specific attention on recent developments to further improve contrast, specificity, and sensitivity. With advances in imaging technologies, such fluorescent imaging probes will open new diagnostic avenues.

Keywords: Alzheimer's disease, amyloid binding, animal models, ATP, brain imaging, near infrared fluorescence, small compounds.

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy